Administration of the selective calpain inhibitor AK295 has been shown to attenuate motor and cognitive dys function after brain trauma in rats. To explore mechanisms underlying the behavioral efficacy of posttraumatic cal pain in hibition, we investigated histologic consequences of AK295 administration. Anesthetized Sprague-Dawley rats received lat eral fluid percussion brain injury of moderate severity (2.2 to 2.4 atm) or served as uninjured controls. At 15 minutes after injury, animals were randomly assigned to receive a 48-hour infusion of either 2 mmollL AK295 (120 to 140 mg/kg) or saline via the carotid artery. At 48 hours and 1 week after injury, spectrin fragments generated specifically by calpain were detected by Western blotting and immunohistochemistry, respectively, in saline-treated, brain-injured animals. Interest-
ingly, equivalent spectrin breakdown was observed in AK295treated animals when cortical and hippocampal regions were evaluated. Similarly, administration of the calpain inhibitor did not attenuate cortical lesion size or the numbers of apoptotic cells in the cortex, subcortical white matter, or hippocampus, as verified by terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick-end labeling and morphology, at 48 hours after injury. These data suggest that an overt reduction in spectrin proteolysis, cortical lesion, or apop totic cell death at 48 hours or 1 week is not required for be havioral improvements associated with cal pain inhibition by AK295 after experimental brain injury in rats. Key Words: Calcium-activated protease-Cytoskeleton-Histology Rat-Traumatic brain injury. somal proteases results from sufficient elevations of in tracellular free calcium and can lead to limited proteoly sis of a host of intracellular proteins (Saido et aI., 1994) and perhaps to cell death (Bartus, 1997) . Among the cellular calpain substrates, perhaps the most well characterized are the cytoskeletal proteins (Shoeman and Traub, 1990) . Proteolysis of the cytoskeletal protein spectrin yields stable, lower molecular weight fragments and is a well established consequence of calpain activa tion, having been demonstrated by a number of labora tories under in vitro and in vivo conditions (Bartus, 1997; Kampf! et aI., 1997; Sorimachi et aI., 1997) .
Calpain activation with concomitant spectrin proteoly sis occurs very early after experimental TBI and persists for several hours to days (Kampf! et aI., 1996; Saatman et a!., 1996a) . Brain regions that exhibit calpain mediated spectrin proteolysis also display progressive cell loss after experimental brain trauma (Saatman et aI., 1996a; Newcomb et aI., 1997) . A large number of cells within these injured brain regions exhibit characteristics of necrotic cell death; however, a distinct population of cells display apoptotic morphology indicative of pro grammed cell death (Rink et aI., 1995; Yakovlev et aI., 1997; Conti et aI., 1998) . Although the involvement of calpains in mediating trauma-induced programmed cell death is currently unknown, evidence shows that calpain may play a role in apoptosis of neurons or neuronal-like cells under certain in vitro conditions (Behrens et aI., 1995; Nath et aI., 1996; Jordan et aI., 1997) .
We have recently shown that posttraumatic adminis tration of AK295, a highly specific inhibitor of calpains that is effective in reducing neuronal pathology in a model of focal cerebral ischemia (Bartus et aI., 1994 (Bartus et aI., , 1995 , significantly reduces both cognitive a nd motor dysfunction induced by lateral fluid percussion (FP) brain injury in the rat (Saatman et aI., 1996b) . Therefore, in the current study, we evaluated the effects of an iden tical administration of AK295 on calpain-mediated spec trin proteolysis, overt cortical damage, and regional apoptotic cell death in the injured rat brain.
MATERIALS AND METHODS

Surgery, brain injury, and administration of inhibitor
Adult male Sprague-Dawley rats (370 to 420 g, n = 35) were anesthetized with 60 mg/kg sodium pentobarbital intra peritoneally, placed in a stereotactic frame, and surgically pre pared for lateral FP brain injury as previously described (Mcln tosh et a!., 1989) . Anesthetized animals were then surgically prepared for intraarterial administration by ligating the left ex ternal carotid artery and retrogradely inserting a cannula to within 1 mm of the carotid bifurcation (Saatman et a!., 1996b) . The cannula was secured in place and externalized, allowing for continuous drug administration into the internal carotid ar tery.
A subgroup of animals were subjected to lateral FP brain injury of moderate severity (2.2 to 2.4 atm, n = 26). The remaining animals (n = 9), having received all surgical pro cedures without brain injury, served as uninjured controls (shams). All animals recovered on heating pads for 15 minutes, at which time they were placed in harnesses, tethered, and connected to continuous-drive syringe pumps. At 15 minutes after injury, animals were randomly assigned to receive either 2 mmollL AK295 (n = 3 control, n = 13 injured) or saline vehicle (n = 6 control, n = 13 injured) delivered at a rate of 9 mLlh for 10 minutes. The flow rate was then reduced to 1.4 mLlh until 24 hours after injury, after which the rate was low ered to 0.7 mLIh until removing the animal from the syringe pump at 48 hours after injury. In this manner, drug-treated animals received 52.4 mg of AK295 (120 to 140 mg/kg) over 48 hours. This administration paradigm was identical to that used previously (Saatman et a!., 1996b) and was designed to maximize the amount of inhibitor received in the acute post traumatic phase (minutes to hours) while maintaining admin istration into the subacute phase (days). During the 48-hour drug administration period, animals were freely moving and had access to food and water.
All procedures described herein were approved by the Uni versity of Pennsylvania Institutional Animal Care and Use Committee and are in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996) .
Immunoblotting for spectrin breakdown products at 48 hours after injury For evaluation of spectrin breakdown at 48 hours after injury by immunoblot analysis, one group of animals (n = 3 injured vehicle-treated, n = 3 injured AK295-treated) was overanes thetized with sodium pentobarbital (200 mg/kg, intraperitoneal ly) immediately after termination of the drug infusion and de capitated. Each brain was quickly removed from the cranium, and tissue pieces of approximately 100 mg were dissected on ice from the ipsilateral hemisphere from the parietal/temporal cortex ("injured cortex," region A, in Fig. I) , the occipital/ parietal cortex ("adjacent cortex," region B), and the hippo campus (region C). The tissue samples were then snap-frozen in slurry of 95% EtOH and dry ice and stored at -80nC.
Western blotting was performed essentially as described pre viously (Saatman et a!., I 996a). Briefly, tissue samples were homogenized in buffer containing 20 mmollL Tris-HCI (pH 8.0), 1% NP-40, 0.137 mollL NaCI, 13 mmollL EDTA and the recommended working concentration of protease inhibitor cocktail (Sigma Chemical Co., St. Louis, MO, U.S.A.; contains leupeptin, aprotinin, and serine protease inhibitor). After cen trifugation, protein concentration of the supernatant was deter mined using a bicinchoninic acid micro protein assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.). Three hundred micro grams of each sample were loaded into a 6% acrylamide gel and subjected to 2 hours of electrophoresis at 150 V, followed by transfer to nitrocellulose at 60 V for 2 hours. Blots were incubated 1 hour in Ab4I, a polyclonal antibody that recog-
vehicle AK295
FIG. 1. Immunoblots for spectrin proteolytic fragments gener ated by calpain at 48 hours after brain injury. A schematic draw ing of a coronal brain slice illustrates the approximate regions of tissue dissected for immunoblot analyses. Calpain-mediated spectrin breakdown was observed in the injured cortex (A), the adjacent cortex (B), and the hippocampus (C) of the ipsilateral hemisphere. The left lanes contain samples from vehicle-treated animals, whereas the right lanes contain samples from AK295treated animals.
nizes the NH2-terminus of the COOH-terminal fragment of a-spectrin generated by calpain (I :500). After incubation in alkaline phosphatase-conjugated goat anti-rabbit IgG (1 :2000, Jackson ImmunoResearch, West Grove, PA, U.S.A.), Fast red (Sigma) was used as the chromogen for visualization.
Immunohistochemistry for calpain-mediated spectrin proteolysis at 7 days after injury
To those animals designated to survive for I week (n = 5 injured vehicle-treated; n = 5 injured AK295-treated; n = 3 control vehicle-treated; n = 3 control AK295-treated), 2% iso fluorane anesthesia was administered at the termination of the 48-hour infusion, allowing the externalized cannula to be tied of� and embedded beneath the skin. At 1 week after injury, ammals were overanesthetized with sodium pentobarbital (200 mg/kg, intraperitoneally) and transcardially perfused with hep arinized saline followed by fixative (4% paraformaldehyde in 0.1 mol/L phosphate buffer, pH 7.4). The brain was then re moved from the cranium, immersed in fixative for 4 hours at 4°C, infiltrated with 20% sucrose at 4°C, and then frozen. Selected coronal tissue sections (40 [Lm) were treated with 0.9% H202 in 50% methanol, blocked in 5% normal goat se rum, and then incubated overnight at 4°C in Ab37, a polyclonal antibody that recognizes the COOH-terminus of the NH -. 2 termmal fragment of a-spectrin generated by calpain (1: 10,000, rabbit IgG) or in Tris-buffered saline with 0.1 % Triton-X as a negative control. The tissue was then incubated in biotinylated goat antirabbit IgG (1 :200, Vector Laboratories, Burlingame, CA, U.S.A.) followed by horseradish peroxidase-conjugated streptavidin (1: 1000, Jackson ImmunoResearch). Nickel sul fate-enhanced diaminobenzidine tetrahydrochloride solution was used to visualize the reaction product.
Under light microscopy (Nikon, Optical Apparatus, Ard more, PA, Y,S,A.), the area of cortical Ab37 immunoreactivity was quantifIed by an evaluator blinded to treatment using im age analysis software (MCID, Imaging Research, Ontario, Canada). Two separate but related measurements of cortical injury were taken. The first measurement yielded the area of cortical Ab37 immunoreactivity on a single coronal section by automatically detecting the region stained with an intensity above a preset threshold (that of uninjured cortical staining). The second cortical measurement, total cortical lesion area, included the area of cortical Ab37 immunoreactivity plus that of the cortical cavity (tissue loss). The total lesion measurement accounted for two possibilities: (I) without accounting for tis sue l�ss, animals with less calpain activation or a slower pro gressIOn of cell loss might paradoxically appear to have a greater extent of spectrin breakdown because of the presence of a greater number of cells in the damaged area, and (2) necrotic tissue at the center of the lesion might have washed away dunng the free-floating tissue staining procedure leading to an underestimation of spectrin breakdown. In addition, the spatial extent of spectrin breakdown products (BDPs) in the hippo campal CA3 region was scored on a scale of a to 4, where a = no spectrin BDPs; 1 = BDPs in the stratum oriens; 2 = BDPs in the stratum oriens (as in 1) and pyramidal cells; 3 = BDPs as in 2 and in the stratum radiatum; and 4 = BDPs as in 3 and in other hippocampal areas.
Cortical lesion and in situ nick-end labeling at 48 hours after injury Those animals to be evaluated histochemically at 48 hours after injury (n = 5 injured vehicle-treated; n = 5 injured AK295-treated; n = 3 control vehicle-treated) were anesthe tized with an overdose of sodium pentobarbital (200 mg/kg,
intraperitoneally) immediately after termination of the drug in fusion and perfused as described above. After postfixation, the brains were processed into paraffin blocks from which 6-[Lm coronal sections were cut.
For analysis of cortical injury, sections were collected from each brain at 2.3, 3.3, 4.3, 5.3, and 6.3 mm posterior to Bregma. Sections were deparaffinized, rehydrated, and stained with he matoxylin and eosin (H&E). The area of cortical damage was circumscribed on each section to include the region of de cre�sed �&E staining as well as adjacent regions exhibiting eosmophlhc, shrunken, or dystrophic neurons. Lesion volume was calculated using the areas obtained from each coronal sec tion and the known distance separating these sections. Quanti fication was performed using image analysis software (MCID) under blinded conditions.
Terminal deoxynucleotidyl transferase-mediated biotinyl ated deoxyuridine triphosphate nick-end labeling (TUNEL) was used to detect damaged DNA. TUNEL histochemistry was pe�formed with a procedure used previously in our laboratory (Rmk et aI., 1995; Conti et aI., 1998) . Three sections spaced at least 36 [Lm apart were selected from each brain at -3.3 mm Bregma. Brietly, sections were heated to 60°C before deparaf finization and rehydration. After proteinase K digestion, tissue was incubated in cacodylate buffer and labeled with biotinyl ated-16-dUTP (20 [LmolfL, Boehringer Ingelheim, Indianapo Its, IN, U.S.A.), TdT (0.3 U/[LL, Boehringer Ingelheim) and 1.5 mmol/L cobalt chloride in cacodylate buffer. Labeling was ter mmated by rinsing with a solution of sodium chloride and sodium citrate. The tissue was blocked in 10% normal goat se . rum and incubated in streptavidin alkaline-phosphatase (1:40, Btogenex, San Ramon, CA, U.S.A.) which was reacted using Fast red (SIgma). Counterstained sections were analyzed under light microscopy by an evaluator blinded to the injury and treatment status of each animal. The number of nonapoptotic a�d ap?ptotic TUNEL-positive cells was manually counted in SIX regIOns: the cortex, subcortical white matter tract, and hip pocampus of both the ipsilateral and contralateral hemispheres. Only those cells which stained with TUNEL and exhibited distinct and verifiable apoptotic morphology, as described in Rink et al. (1995) , were classified as apoptotic. Reported counts r�present �he total number of cells for the three nonadjacent tissue sectIOns evaluated for each animal.
Statistical analyses
Lesion areas and cell counts were considered parametric data and were therefore expressed as means with standard devia tio�s. Comparisons of cell counts, cortical injury, or cortical leSIOns were made using Student's t tests. A P value of less than 0.05 was considered statistically significant.
RESULTS
Calpain-mediated spectrin breakdown
Immunoblot analysis of tissue samples taken from the injured cortex (region A) using an antibody specific for calpain-mediated spectrin BDPs revealed spectrin break down in all brain-injured animals at 48 hours after injury. The intensity of the single band at approximately 150 kD was equivalent for all animals regardless of treatment, indicating that the animals receiving AK295 had compa rable levels of spectrin breakdown as those receiving vehicle ( Fig. 1 A) . Similarly, no reduction in the level of spectrin breakdown in animals treated with AK295 was observed in tissue samples from either region B of the cortex (Fig. lB) or the hippocampus (Fig. IC) .
At 7 days after injury, no staining for spectrin BDPs was observed in any region in control (sham) animals. In contrast, all brain-injured animals showed evidence of spectrin proteolysis surrounding a necrotic cavity in the ipsilateral cortex at 1 week after injury (Fig. 2) . The area exhibiting spectrin breakdown began, on average, at -0.8 mm Bregma and continued beyond -7.0 mm Bregma. The region exhibiting immunoreactivity for spectrin fragments was diffusely stained but interspersed with small puncta and contained no labeled cells other than an occasional neuron. There were no apparent differences in the pattern or intensity of cortical calpain-mediated spec trin proteolysis observed in vehicle-treated animals (Fig.  2, top row) when compared to those given AK295 (Fig.  2, bottom row) . Quantification of the area of spectrin BDP immunoreactivity (Fig. 3A) and of the total cortical lesion area (which includes the area of spectrin BDP immunoreactivity plus that of the cortical cavity) ( Fig.   3B ) revealed no significant differences between brain injured animals receiving vehicle and those receiving AK295 at any of the three rostrocaudal levels that were examined.
In 8 of the 10 brain-injured animals, calpain-mediated breakdown was also observed in the CA3 region of the ipsilateral hippocampus. No intact cells were immunola beled. Rather, punctate spectrin BDP immunoreactivity was detected, most frequently in the stratum oriens, fol lowed by the pyramidal cell layer and then the stratum radiatum. When animals were rated on a 0 to 4 scale according to the spatial extent of spectrin breakdown in the CA3 region, no significant effect of treatment was observed (1.8 ± 1.5 for vehicle treatment and 1.4 ± 1.1 for AK295 treatment, mean ± SD; P > 0.05).
Cortical lesion
At 48 hours after FP brain injury, all animals exhibited loss of H&E-stained neurons in the ipsilateral cortex. Loss of H&E staining was observed at all rostrocaudal levels examined, from 2.3 to 6.3 mm posterior to 
1.8mm
Bregma. Quantification of the area of cortical damage, which included regions containing eosinophilic and pyk notic neurons, revealed no significant differences be cause of treatment with vehicle versus calpain inhibitor at any of the rostrocaudal levels (Fig. 4) . The cortical lesion volume, calculated from 2.3 to 6.3 mm posterior to Bregma, was 15.6 ± 3.8 mm 3 for vehicle-treated animals and 18.6 ± 5.8 mm 3 for AK295-treated animals (P > 0.05).
Apoptosis
TUNEL histochemistry labeled cells with fragmented DNA, and a subpopulation of TUNEL-positive cells dis played distinct morphologic features of apoptosis. Apop totic cells were round and shrunken, with round, con densed, intensely stained nuclei (Fig. SA, left) . Cells which lacked these features and exhibited predominantly cytoplasmic TUNEL staining (Fig. SA, right) were con sidered nonapoptotic. At 48 hours, very few, if any, TUNEL-Iabeled cells with apoptotic morphology were present in uninjured (sham) animals (Figs. 5B and 5C). In contrast, brain-injured animals treated with vehicle exhibited a significantly greater number of apoptotic cells in the ipsilateral cortex (P < 0.05), hippocampus (P < 0.05), and white matter (P < 0.005) than did sham animals ( Fig. 5B ). Interestingly, there was also a slight but significant increase in the number of apoptotic cells attributable to brain injury in the contralateral cortex (P < 0.05). Brain-injured animals who received AK295 dis played a significant increase in the number of apoptotic cells only in the ipsilateral subcortical white matter when compared to sham animals (P < 0.05) but exhibited no differences in any region from vehicle-treated, brain injured animals.
Similarly, vehicle-treated, brain-injured animals ex hibited a significant increase in the number of nonapop totic, TUNEL-positive cells in the ipsilateral cortex (110 ± 100 versus 4 ± 1 in shams; P < 0.05), hippocampus (6 ± 3 versus 1 ± 1 for sham; P < 0.05), and white matter (84 ± 34 versus 7 ± 6 for sham; P < 0.005). AK295treated animals showed a significant increase in TUNEL- stained nonapoptotic cells in the ipsilateral white matter (89 ± 48 versus 7 ± 6 for shams; P < 0.05). The only difference noted between brain-injured animals treated with calpain inhibitor and those treated with vehicle was a small but significant decline in nonapoptotic, TUNEL labeled cells in the ipsilateral hippocampus of AK295treated animals (1 ± 2 versus 6 ± 3 for vehicle-treated; P < 0.05).
DISCUSSION
We previously demonstrated that administration of the selective calpain inhibitor AK295 conferred significant J Cereb Blood Flow Metab. Vol. 20. No.1, 2000 protection against both neuromotor and cognitive deficits resulting from experimental brain injury (Saatman et aI., 1996b) . However, in the present study, we found no evi dence that treatment of brain-injured animals with AK295 attenuated cortical lesion volume, regional apop tosis, or calpain-mediated spectrin proteolysis in the vul nerable regions of the cortex and hippocampus at 48 hours or 1 week after injury. These data suggest that overt histologic protection in the areas of maximal dam age after brain trauma is not a necessary condition for behavioral improvements associated with posttraumatic calpain inhibition. Our findings with the compound AK295 reiterate the importance of using multiple, clini cally relevant outcome measures when evaluating the therapeutic potential of novel compounds in trauma.
Although evidence for a role for calpains in the pa thology of CNS injury has been increasing (Bartus, 1997; Kampf! et aI., 1997) , few studies have investigated the effects of calpain inhibitors in models of traumatic CNS injury. Administration of cysteine protease inhibitors has been shown to reduce axonal degeneration and neuro filament degradation after spinal cord injury in rats (Iwasaki et aI., 1987) . A more recent study demonstrated that treatment with calpain inhibitor II attenuated cortical neuropathology and cytoskeletal proteolysis 24 hours af ter cortical impact brain injury in rats (Posmantur et aI., 1997) . Our data demonstrating a lack of overt neuropro tection attributable to calpain inhibition with AK295 in brain-injured rats are in sharp contrast to these studies. In comparison to AK295, however, the inhibitors used in previous trauma studies were less specific for calpain (Bartus et aI., 1995; Wang and Yuen, 1995; Sorimachi et aI., 1997) and may have affected other proteases in- volved in the processes of cell damage and death. It is also possible that differences in pharmacokinetics and tissue penetration of the inhibitors and in the injury mod els contributed to the disparate findings. U sing an administration paradigm similar to that em ployed in the present study, Bartus et aI. (1994) demon strated that AK295 significantly reduced infarct size when given after focal cerebral ischemia in the rat. The related calpain inhibitor CX216 has been shown to pro tect rat CAl neurons when administered after global ce rebral ischemia (Bartus et aI., 1995) . Although treatment with these and other calpain inhibitors has been shown to confer neuroprotection in models of cerebral ischemia (Lee et aI., 1991; Rami and Krieglstein, 1993; Hong et ai., 1994; Markgraf et aI., 1998) , we found no reduction in spectrin proteolysis or overt cell death after treatment of brain-injured rats with AK295. These data suggest that the histologic effects of AK295 in the traumatically in jured brain may be uniquely different from those in the ischemic brain, indicating the necessity for thorough evaluation of potentially therapeutic calpain inhibitors in models of TBI as well as cerebral ischemia.
The lack of overt neuroprotection observed with AK295 administration may be attributable, in part, to a delay in the establishment of therapeutic levels of cal pain inhibitor in areas of maximal damage. Calpain activation in the rat brain after TBI has been detected as early as 15 minutes and shown to peak before 1 day after injury, with maximal appearance of calpain-mediated spectrin breakdown products at approximately 1 day after injury (Kampf! et aI., 1996; Saatman et aI., 1996a) . The para digm for administration of the calpain inhibitor AK295, beginning at 15 minutes and continuing for 48 hours, was selected to target early posttraumatic calpain activation and maintain inhibition beyond the period of maximal activation. The ability of AK295 to inhibit the degrada tion of neurofilament protein in rat spinal cord has been shown to be dose-dependent, with near complete inhibi tion at concentrations of 25 to 50 fLmollL (James et aI., 1998) . Although extensive and prolonged compromise of the blood-brain barrier after experimental brain injury (Cortez et aI., 1989; Tanno et aI., 1992; Baldwin et ai., 1996) should have facilitated penetration of the drug into damaged tissues, the time course and level of AK295 achieved in the traumatically injured brain in the current study are unknown. Therefore, a delay in reaching local, therapeutic calpain inhibitor levels may have allowed sufficient calpain activation to initiate cascades of de structive intracellular events that ultimately resulted in cell death.
Our data showing significantly more apoptotic cells in the ipsilateral cortex and white matter 48 hours after lateral FP brain injury was consistent with previous studies using this model (Rink et aI., 1995; Conti et aI., 1998) . We also found small increases in the numbers of apoptotic cells in the ipsilateral hippocampus and contralateral cortex. However, calpain inhibitor treat ment did not significantly attenuate apoptotic cell death in any of these regions. Although the role of calpain in apoptosis after TBI is currently unknown, calpain has been implicated in pathways of apoptotic cell death in vitro using a number of cell types including thymo cytes (Squier et aI., 1994) , hepatocytes (Gressner et aI., 1997) , neutrophils (Brown et aI., 1997) , and neurons and neuroblastoma cell lines (Behrens et aI., 1995; Nath et aI., 1996; Jordan et aI., 1997) . The effectiveness of calpain inhibitors in preventing apoptosis may depend on the cell type, initiating stimulus, and characteristics of the inhibitor (Nath et aI., 1996; Sorimachi et aI., 1997) , suggesting that results from in vitro studies may not adequately reflect the environment after trauma in which multiple cell types experiencing both physical and biochemical stimuli undergo apoptosis (Conti et aI., 1998) .
Although posttraumatic calpain inhibition did not at tenuate damage in the vulnerable regions of the cortex and hippocampal CA3 pyramidal layer, it is possible that the behavioral improvements documented in our previ ous study were associated with subtle histologic benefits resulting from AK295 treatment that were not detected in the present study. Lateral FP brain injury has been shown to result in diffusely distributed axonal damage (Yagh mai and Povlishock, 1992; Pierce et aI., 1996; Saatman et al., 1998) and progressive cell loss in regions other than the cortex and hippocampus (Dietrich et al., 1994; Hicks et aI., 1996; Bramlett et aI., 1997; Smith et aI., 1997; Conti et aI., 1998) . Our histologic assessment tech niques may not have been sensitive enough to detect treatment effects related to scattered axonal injury or delayed (secondary) degeneration. A small reduction in the number of nonapoptotic, TUNEL-positive cells in AK295-treated animals was detected in the ipsilateral hippocampus, which may reflect an effect of calpain in hibition on cells in early stages of cellular injury or with sublethal damage. Future studies should address these possibilities.
The robust behavioral improvements derived from posttraumatic calpain inhibition were not accompanied by an overt reduction in cortical cell loss or spectrin degradation. There is evidence to suggest that cell loss may not directly correlate with functional outcome after experimental brain injury (Lyeth et aI., 1990; Sabel, 1997) . For example, despite the ability of untreated, brain-injured animals to partially recover neuromotor function over days, weeks, and months after trauma (McIntosh et aI., 1989; Pierce et aI., 1998) , histologic evidence shows that both necrotic and apoptotic cell death continue during this same time period (Dietrich et aI., 1994; Hicks et aI., 1996; Bramlett et aI., 1997; Smith et aI., 1997; Conti et aI., 1998) . Therefore, it is likely that J Cereb Blood Flow Metab. Vol. 20, No. 1, 2000 inhibition of calpain may improve recovery of function in a manner independent of direct sparing of vulnerable cells. Pretreatment with calpain inhibitors has been shown to preserve neuronal ability to exhibit long-term potentiation (Lee et aI., 1991) and facilitate recovery of synaptic transmission (Arai et aI., 1990; Hiramatsu et aI., 1993) after CNS injury. Furthermore, because calpain acts on a great number of intracellular substrates, its inhibition may have led to functionallbehavioral efficacy in part by preventing the proteolysis of intracellular sig naling or membrane-associated molecules not evaluated in the current study.
We have shown that the behavioral efficacy observed at 1 week after brain injury by rats treated for 48 hours with the calpain inhibitor AK295 (Saatman et aI., 1996b) was not accompanied by an overt attenuation of calpain mediated spectrin breakdown, cortical lesion size, or number of apoptotic cells. These data suggest that the behavioral effects produced by posttraumatic administra tion of AK295 may be mediated through subtle or diffuse histologic and biochemical alterations that may be uniquely different from those observed in experimental cerebral ischemia. Importantly, these findings suggest that the sparing of a large number of cells in the areas of maximal damage inflicted by trauma may not be a nec essary condition for improving functional outcome by the inhibition of calpain after brain injury.
